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Abstract Prevalence of dynamic left ventricular
outflow tract obstruction (DLVO) during dobutamine
stress-echo (DSE) seems disproportionally high
among diabetic patients. We retrospectively identi-
fied 212 diabetic (D?) and 212 non diabetic (D-)
subjects, who underwent DSE for suspected coronary
artery disease (CAD); we evaluated DSE-induced
DLVO prevalence and correlates. During DSE, 105
patients in D? (50%) and 83 in D- group (39%,
P = 0.032) developed a DLVO, with similar maxi-
mum gradient (94 ± 49 mmHg in D? vs. 86 ±
49 mmHg in D-, P = NS). D? and D- patients
with DLVO showed reduced LV end-diastolic and
end-systolic dimension. Compared with diabetic
subjects without DLVO, diabetic patients with DLVO
had higher left ventricular (LV) ejection fraction
(EF), lower LV mass index; diastolic function was
normal in a higher proportion of cases. Non diabetic
patients with moderate or severe DLVO had higher
LV EF compared with patients without DLVO. At
multivariate analysis, in D? patients, the only
independent predictor was a smaller LV end-diastolic
diameter (HR 0.779, CI 0.655–0.926, P = 0.005); in
D- patients lower age (HR 0.878, CI 0.806–0.957,
P = 0.003), higher LV EF (HR 1.087, CI 1.003–
1.177, P = 0.042) and lower peak WMSI (HR 0.017,
CI 0.001–0.325, P = 0.007) were associated to
presence of DLVO. In D? patients, during a median
follow-up of 924 ± 134 days, we observed 11 new
cardiac events, only 1 in patients with DLVO (P =
0.0041). DSE-provoked DLVO had a very high
prevalence in patients evaluated for suspected CAD,
especially among diabetic patients; echocardio-
graphic predictors were a reduced LV dimension in
D? and a preserved systolic function, both at rest and
at peak stress, in D- patients.
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Introduction
Dobutamine stress-echocardiography (DSE) is an
established tool for diagnostic and prognostic assess-
ment [1] of patients with known or suspected coronary
artery disease (CAD); its diagnostic and prognostic
value has been repeatedly confirmed also in special
populations, such as diabetic subjects [2–4], elderly
people [5, 6], patients with low-gradient aortic stenosis
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[7, 8] and patients with left ventricular (LV) systolic
dysfunction [9].
In a proportion of about 20% of patients, dobutamine
administration evokes an exaggerated contractile
response, with a dynamic LV outflow tract obstruction
(DLVO) and development of an intra-ventricular
pressure gradient [10, 11]: predisposing factors seem
to be female sex, small LV dimension and a preserved
LV global systolic function. In patients without CAD,
DLVO prevalence seems to be significantly higher [12,
13]; although from a prognostic point of view, DLVO
yields a excellent value, because it seems to indicate a
fully preserved LV contractile reserve, it has been
reported a reduction in diagnostic accuracy, especially
in presence of a coronary one-vessel disease [10].
Among diabetic patients, CAD represents the main
cause of morbidity and mortality; moreover, when
symptoms appear, coronary involvement is often too
severe to allow an effective treatment [14]. American
Diabetes Association defined a list of criteria to select
diabetic patients who would undergo a screening test for
CAD [15], alternatively with DSE or myocardial
perfusion scintigraphy. However, in a limited series of
diabetic patients undergoing DSE for CAD screening, a
disproportionally high prevalence of DLVO has been
previously reported [16].
Aim of this study was to verify prevalence and
clinical and echocardiographic correlates of DLVO
DSE-induced in a population of diabetic and non-
diabetic subjects with suspected CAD.
Methods
Study patients
Between October 2006 and October 2007, 212
consecutive diabetic subjects (D? group) underwent
DSE for CAD screening, according to the recom-
mendations of American Diabetes Association [15].
Among the other patients who performed a DSE in
our Ambulatory from January 2003 to October 2007,
a control group (D- group) was selected, identifying
212 non-diabetic subjects, with suspected CAD, who
underwent DSE for chest pain evaluation or preop-
erative assessment. All patients gave their informed
consent and the study is consistent with the principles
of the Declaration of Helsinki of clinical research
involving human subjects.
At the time of DSE we collected data about previous
clinical history, level of glicate hemoglobin (HbA1c) as
an indicator of metabolic control, presence of diabetic
complications and current therapy, including cardiovas-
cular and diabetic treatment. Hypertension was defined
as systolic blood pressure C140 mmHg, diastolic blood
pressure C90 mmHg or the use of antihypertensive
medications; patients were considered to have dyslipi-
demia if their total cholesterol was C200 mg/dl or if they
were receiving lipid-lowering-medications. Smoking
history was considered positive both for current and
previous smokers. Presence of diabetic treatment indi-
cated both insulin and/or oral agents.
Dobutamine stress protocol
B-blockers therapy was withheld the day before the
examination. After the baseline echocardiogram
(Sequoia, Siemens, Mountain View, CA, USA), we
started the intravenous infusion of incremental doses of
dobutamine beginning with low doses (LD) (5 and
10 lg/Kg/min, each stage for 3 min), followed by high
doses (HD) (20, 30 and 40 lg/Kg/min, each stage for
3 min), during continuous echocardiographic and elec-
trocardiographic monitoring and blood pressure mea-
surement at the end of each stage [1]. Atropine (0.25 mg/
min until maximum dose of 1 mg) was infused intrave-
nous to achieve the target heart rate (85% of 220-age) in
patients with sub-maximal response by dobutamine
infusion alone all patients underwent DSE according to
standard protocol. Test end-points were achievement of
target heart rate, positive response for ischemia as
development of new asynergia in two or more myocar-
dial segments, excessive increase (systolic blood pres-
sure, SBP, [240 mmHg) or significant reduction of
blood pressure (more than 40 mmHg than preceding
phase o SBP \90 mmHg), repetitive ventricular or
supraventricular ectopy and development of intolerable
side effects. If the patients developed inducible ischemia,
propranolol was infused in incremental doses of 0.5 mg,
until symptoms, ECG and echocardiographic modifica-
tions resolved.
During routine exams, in case of a hyperkinetic
response, at baseline and during the last minute of
each high dose (HD) stage, intraventricular systolic
flow was measured by continuous wave Doppler.
Dobutamine-induced DLVO was defined as appear-
ance of an intraventricular flow acceleration of at
least 3 m/s, with an abnormal shape and a maximum
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velocity in late systole, without anterior motion of the
mitral leaflets. With color-Doppler flow mapping, the
LV obstruction was located and differentiated from any
mitral regurgitation; maximum gradient was calculated
from maximal velocity by the modified Bernoulli
equation. On the basis of maximum gradient, patients
were divided in three subgroups: no DLVO, in absence
of any gradient or with a gradient up to 35 mmHg,
moderate DLVO with a gradient included between 36
and 65 mmHg and severe DLVO for a maximum
gradient higher than 65 mmHg.
Left ventricular end-diastolic and end-systolic
dimensions were measured from 2D guided Mmode,
whenever possible, or from 2D parasternal long axis
view. Left ventricular (LV) volumes were measured
according to Simpson’s Rule method and LV ejection
fraction (EF) was calculated from such volume mea-
surements. LV mass was calculated according to the
formula of American Society of Echocardiography [17]
and it was indexed by height-2.7 (LVMH). LV relative
wall thickness (LV RWT) was estimated at rest by the
formula 29 PWTd/LVEDD (PWTd: diastolic posterior
wall thickness; LVEDD: LV end-diastolic diameter).
Diagnosis of LV hypertrophy was made in presence of a
LVMH higher than 49.2 g/h-2.7 in men and 46.7 g/h-2.7
in women; hypertrophy was considered eccentric with
LV RWT \ 0.45 and concentric with LV RWT [ 0.45.
In D? patients, diastolic parameters were evaluated;
we measured peak velocities of the early (E) and late
(A) transmitral waveforms assessed by pulsed Doppler,
with the sample volume placed at the tips of the mitral
valve leaflets, their ratio (E/A) and E deceleration time
(EDT). We also evaluated E wave propagation rate
(EVp) by color Doppler M-mode across the mitral valve,
and the ratio of E/EVp, as indicator of LV filling pressure.
We also categorized the severity of diastolic dysfunction
into the following 4 stages: I (abnormal relaxation) was
manifested by an E/A ratio\0.75 and a prolonged DT
([220 ms) with normal filling pressures; II (pseudo
normal) was characterized by an E/A ratio between
0.75 and 1.5, short DT (\150 ms), Vp \45 cm/s or
E/Vp\ 1.5; III and IV (restrictive pattern), which is
reversible or fixed depending on its response to the
Valsalva maneuver, had an E/A ratio[1.5 [18].
Echocardiographic analysis
Echocardiographic images were registered on video-
tapes during the whole test; at baseline, at the end of
low-dose (LD) and HD and after recovery, digital
images obtained in parasternal long and short axis
and apical four and two chambers view were stored
on disk, to allow a quad-screen visualization. LV
regional wall motion was assessed according to
the recommendations of the American Society of
Echocardiography, with a 16 segments model;
each segment was given a kinetic score: 0 = not
visualized, 1 = normokinetic, 2 = hypokinetic, 3 =
akinetic, 4 = dyskinetic and 5 = aneurism. Wall
Motion Score Index (WMSI) was calculated at
baseline, after LD and HD infusion as ratio between
the cumulative sum score and the number of visual-
ized segments.
Inducible ischemia was defined as the develop-
ment, in at least two segments, of new asynergia or
biphasic response (basal asynergia improving at LD
and becoming worse at HD); ischemia was consid-
ered mild when up to three segments became
asynergic during the test and severe for a more
extensive involvement.
Follow-up data
Between July and September, 2009 all patients were
contacted by telephone to verify the occurrence of
new major events (death, both cardiac and non-
cardiac, and non-fatal MI). A combined end-point,
including cardiovascular death and major cardiovas-
cular event (STEMI, and coronary revascularization)
was calculated to evaluate DSE prognostic value in
this population.
Statistical analysis
Data were analyzed with SPSS program (SPSS Inc.,
Chicago, IL, USA). Parametric data were reported as
mean ± standard deviation. The comparison between
two groups was made with Student test for non-
coupled parametric data; the comparison between
multiple groups was made with Anova test. Signif-
icance was set at P \ 0.05. Non parametric data were
analyzed with Fisher exact test.
Multivariate analysis was performed using a multiple
logistic regression model (likelihood ratio method, with
variable in by P \ 0.05, and out P [ 0.10 to avoid
biases due to colinearity) to identify independent
predictors of DLVO development.
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Results
105 patients in D? (50%) and 83 in D- group (39%,
P = 0.032) developed a DLVO, with similar maxi-
mum gradient (94 ± 49 mmHg in D? vs. 86 ±
49 mmHg in D-, P = NS); considering only patients
who were not taking beta-blockers (180 in group D?
and 151 D-), D? subjects reached a higher maxi-
mum gradient (56 ± 60 vs. 43 ± 56 mmHg, P =
0.04).
Baseline characteristics
Clinical characteristics are shown in Table 1. The
two groups were comparable for age and sex
distribution; D? patients showed significantly higher
body mass index (BMI) and increased prevalence of
other cardiovascular risk factors. Typical or atypical
angina was less frequent in D? subjects that often
reported exertional dyspnea. D? subjects assumed
more frequently angiotensin converting enzyme
(ACE)-inhibitors (42% in D? vs. 31% in D-,
P = 0.015), angiotensin II receptors antagonists
(29% in D? vs. 18% in D-, P = 0.007) and
dihydropyridines (23% in D? vs. 13% in D-,
P = 0.006), while D- patients assumed more fre-
quently verapamil or diltiazem (2% in D? vs. 10% in
D-, P = 0.001) and beta-blockers (13% in D? vs.
28% in D-, P \ 0.0001); diuretics were equally
assumed in the two groups.
Baseline echocardiographic examination (Table 1)
showed similar left ventricular ejection fraction (LV
EF) in D? and D- subjects, with significantly
increased LV wall thickness and LV mass indexed for
height-2.7 (LVMH) in D? patient; an LV eccentric
hypertrophy was significantly more frequent among
D? patients (30% in D? vs. 14% in D-, P \ 0.004),
while concentric hypertrophy had a low and similar
prevalence (7% in D? vs. 4% in D-, P = NS).
DSE parameters
Table 2 summarizes hemodynamic findings during
DSE. Peak dobutamine dose was similar in the
two groups. D? patients showed higher cardiac rate
all during the test (Fig. 1a) and only atropine
Table 1 Clinical and
echocardiographic
characteristics in diabetic
(D?) and non diabetic
(D-) patients
EDD end-diastolic
diameter, EDS end-systolic
diameter, IVSTd and IVSTs
diastolic and systolic
interventricular septal
thickness, PWTd and PWTs
diastolic and systolic
posterior wall thickness,
RWT relative wall
thickness, LVMH left
ventricular mass corrected
for height-2.7, LV EF left
ventricular ejection fraction
D? (n = 212) D- (n = 212) P
Age (years) 66 ± 10 68 ± 11 0.052
Male sex (%) 100 (47) 86 (41) 0.171
BMI (m/kg2) 29 ± 5 25 ± 3 \0.0001
Hypertension (%) 175 (84) 135 (64) \0.0001
Dyslipidemia (%) 163 (79) 92 (44) \0.0001
Smoking habitus (%) 124 (59) 85 (41) \0.0001
Carotid vascular disease (%) 30 (15) 24 (15) 0.936
Peripheral vascular disease (%) 43 (21) 23 (14) 0.091
Symptoms
Angina (%) 19 (9) 81 (39) \0.0001
Effort dyspnoea (%) 49 (23) 24 (11) 0.003
Atypical symptoms (%) 10 (5) 49 (23) \0.0001
b-blockade therapy (%) 27 (13) 62 (28) \0.0001
EDD (mm) 50 ± 5 50 ± 6 0.837
ESD (mm) 33 ± 6 35 ± 7 0.058
IVSTd (mm) 9 ± 1 9 ± 2 0.008
IVSTs (mm) 14 ± 2 13 ± 2 \0.0001
PWTd (mm) 9 ± 1 8 ± 1 \0.0001
PWTs (mm) 14 ± 2 13 ± 2 0.002
RWT 0.37 ± 0.1 0.33 ± 0.1 \0.0001
LVMH (g/m-2.7) 44 ± 10 39 ± 11 \0.0001
LV EF (%) 58 ± 9 58 ± 11 0.808
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administration determined a similar rate response; to
note that all the data about rate response to DSE were
analyzed considering only patients not taking beta-
blockers.
Among D- patients, reproducibility of symptoms
during DSE was higher among patients with DLVO
(24 vs. 10%, P \ 0.05), while among D? subjects
both the prevalence of DSE-evoked symptoms and
reproducibility was really very low. The prevalence
of DSE-induced EKG modifications was similar in
the two groups and an ischemic response, both mild
and severe, was evoked in a similar proportion of
cases. Among D? patients, a significantly higher
proportion of patients without DLVO concluded the
test without any side effect (84 vs. 63%, P \ 0.001),
while in D- the difference was not significantly
different (78% vs. 67%, P = 0.08); hypotension
occurred in a similar proportion of subjects in both
groups (D?: no DLVO 3% vs. DLVO 4% P = NS;
D-: no DLVO 5% vs. DLVO 4% P = NS). In only 2
patients with DLVO, both in D? and D- group, the
test was prematurely stopped for arrhythmias (1
ventricular and 1 supraventricular in D? and 2
supraventricular in D-), but a heart rate above 100 b/
min has been already reached in all cases and
maximum gradient could be evaluated at peak stress.
Clinical and echocardiographic parameters
according to DLVO development
We subdivided each group in three subgroups,
according to the absence of DLVO, presence of
moderate and severe DLVO (Table 3). D- patients
with DLVO were significantly younger; to note that,
among subjects older than 75 years, ischemia
developed much more frequently compared to
younger subjects (30/62 vs. 28/150, P \ 0.0001),
probably precluding a DLVO development. No
clinical variable was significantly different between
subgroups among D? patients, including diabe-
tes duration (non DLVO: 11 ± 11 years; moderate
DLVO 16 ± 11 years; severe DLVO 12 ± 12 years,
all P = NS), treatment with insulin (non DLVO:
21%; moderate DLVO 24%; severe DLVO 24%, all
P = NS) or metformin (non DLVO: 74%; moderate
DLVO 62%; severe DLVO 71%, all P = NS); also
degree of metabolic control was similar (HbA1c in
subjects without DLVO 8 ± 1%; moderate DLVO
7 ± 1%; severe DLVO 8 ± 1%, all P = NS).
Among D- subjects, we did not find any difference
in medications assumed by the patients. D? patients
with DLVO assumed more frequently diuretics (25
vs. 11%, P = 0.01) and patients on diuretic treatment
showed a significant lower LV diastolic volume
index (45 ± 6 ml/m2 vs. 52 ± 14 ml/m2, P = 0.002),
while LV EF (59 ± 9 vs. 58 ± 9%, P = NS) and
LVMH (47 ± 8 gr/h-2.7 vs. 44 ± 11 gr/h-2.7, P = NS)
were similar.
D? and D- patients with DLVO, both moderate
and severe, showed reduced LV end-diastolic
and end-systolic dimension. Diabetic patients with
severe DLVO had higher LV EF and lower LVMH
compared with diabetic subjects without DLVO; non
diabetic patients with moderate or severe DLVO had
higher LV EF compared with patients without
DLVO. LV hypertrophy was significantly less fre-
quent in D? patients with DLVO (23 in DLVO? vs.
42 in DLVO-, P = 0.029), while in D- subjects the
difference was not significant (8 in DLVO? vs. 20 in
DLVO-, P = NS).
Table 2 Clinical and
hemodynamic data during
DSE in diabetic (D?) and
non diabetic (D-) patients
D? (n = 212) D- (n = 212) P
Peak dobutamine dose (lg/kg/min) 34 ± 7 35 ± 7 0.787
Resting SBP (mmHg) 135 ± 16 135 ± 18 0.999
Peak SBP (mmHg) 153 ± 33 143 ± 31 0.001
Peak DSE EKG mod. (%) 73 (34) 64 (30) 0.406
Peak DSE symptoms (%) 12 (6) 38 (18) 0.0001
Atropine administration (%) 77 (36) 61 (29) 0.097
Ischemia 0.801
No ischemia (%) 146 (69) 145 (68)
Mild ischemia (%) 22 (10) 26 (12)
Severe ischemia (%) 44 (21) 41 (19)
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Among D? subjects, a higher proportion of
patients with DLVO showed normal diastolic func-
tion (38% in patients with vs. 22% in patients without
DLVO, P = 0.02). A type I dysfunction had a similar
prevalence in DLVO? and DLVO- patients (46% of
patients with and 49% of patients without DLVO,
P = NS), while a type II dysfunction was signifi-
cantly more common in patients without DLVO (15%
of patients with and 29% of patients without DLVO
P = 0.02); 1 only patients showed type 3 dysfunc-
tion. EVp (Table 4), that reflects LV relaxation
properties, was significantly higher, and within
normal values, in patients with DLVO; subjects with
severe DLVO had significantly higher values than
patients with moderate DLVO. Ratio of E wave to
EVp (E/EVp) was significantly lower in patients with
severe DLVO. We also evaluated mitral annular E0
velocity (Table 4), but we were not able to find any
significant differences according to presence of
DLVO. D? and D- patients with DLVO showed
lower WMSI during all DSE stages and developed
less frequently inducible ischemia (Table 3). Peak
dobutamine dose was similar in both groups, regard-
less the presence of DLVO (D-: 34 ± 8 c/kg/min in
DLVO- vs. 36 ± 6 c/kg/min in DLVO?; D?:
34 ± 8 c/kg/min in DLVO- vs. 35 ± 7 c/kg/min
in DLVO?, all P = NS); percentage of non diag-
nostic test was significantly higher only among
D- patients in presence of DLVO (40% vs. 19%,
P = 0.002), while D? subjects showed a very low
and uniformly distributed proportion of non conclu-
sive test (10% in DLVO- vs. 8% in DLVO?,
P = NS).
D? patients with severe DLVO showed a more
pronounced heart rate increase during HD dobuta-
mine infusion than D? patients without DLVO; D-
patients’ rate increase during DSE was similar despite
the presence of DLVO (Fig. 1b, c). DSE determined
more frequently chest pain in D- subjects with
DLVO, while among D? patients very few subjects
reported symptoms during the test.
Predictors of DLVO development
A multivariate analysis, including age and all echo-
cardiographic parameters that were significantly
different between patients with and without DLVO
(age, end-diastolic and end systolic diameter, EDD
and ESD, LVMH, baseline, LD and HD WMSI, LV
EF, and, in D? patients, treatment with diuretics
and EVp), showed that, in D? patients, the only
independent predictor was a smaller EDD (HR 0.779,
CI 0.655–0.926, P = 0.005); in D- patients lower
age (HR 0.878, CI 0.806–0.957, P = 0.003), higher
LV EF (HR 1.087, CI 1.003–1.177, P = 0.042) and
lower HD WMSI (HR 0.017, CI 0.001–0.325,
P = 0.007) were independently associated to pres-
ence of DLVO.
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Fig. 1 Heart rate increase during DSE in D? and D- subjects
(a); heart rate increase in D? (b) and D- (c) patients without
DLVO and with moderate and severe DLVO
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Follow-up
During a median follow-up of 924 ± 134 days, we
observed 5 death, in three cases for cardiovascular
reason; 8 patients underwent to percutaneous coro-
nary artery revascularization procedures (PTCA, in
one case performed in a patient that subsequently
died), but nobody referred a new myocardial ische-
mic event. In patients who developed DLVO we
observed only 1 PTCA; all observed deaths were in
patients without DLVO, two with inducible ischemia
and one in a patient who stopped the test for side
effects hypotension (1 events in subjects with DLVO
and 10 in subjects without DLVO, P = 0.0041). In
Table 3 Clinical and echocardiographic characteristics according to presence or absence of DLVO
Diabetic subjects (n = 212) Non diabetic subjects (n = 212)
Non DLVO
(n = 107)
Moderate DLVO
(n = 24)
Severe DLVO
(n = 81)
Non DLVO
(n = 129)
Moderate DLVO
(n = 25)
Severe DLVO
(n = 58)
Age 67 ± 10 68 ± 10 64 ± 9 70 ± 10 64 ± 10* 65 ± 11*
Symptoms
Angina (%) 13 (12) 2 (8) 4 (5) 47 (37) 8 (33) 26 (45)
Effort dyspnoea (%) 27 (25) 7 (29) 15 (19) 14 (11) 3 (13) 7 (12)
Atypical symptoms (%) 5 (5) 2 (8) 3 (4) 26 (20) 6 (25) 17 (29)
EDD (mm) 52 ± 5 48 ± 5* 47 ± 4* 51 ± 6 48 ± 5 48 ± 4*
ESD (mm) 35 ± 7 30 ± 5* 30 ± 4* 36 ± 8 34 ± 5 32 ± 4*
IVSTd (mm) 9 ± 1 9 ± 1 9 ± 1 9 ± 2 8 ± 1 9 ± 2
PWTd (mm) 9 ± 1 10 ± 1 9 ± 1 8 ± 1 8 ± 1 8 ± 2
RWT 0.35 ± 0.05 40 ± 0.06* 40 ± 0.06* 0.33 ± 0.08 0.32 ± 0.05 0.34 ± 0.08
LVMH (g/m-2.7) 46 ± 10 44 ± 9 41 ± 10* 40 ± 11 35 ± 9 37 ± 13
LV EF (%) 55 ± 10 63 ± 7* 64 ± 7* 55 ± 11 65 ± 7* 65 ± 6*
Maximum gradient (mmHg) 4 ± 10 54 ± 10 120 ± 38 4 ± 9 53 ± 9 117 ± 40
DSE-provoked chest pain (%) 5 (5) 1 (4) 6 (7) 15 (12) 7 (28)* 16 (28)*
Rest WMSI 1.20 ± 0.35 1.03 ± 0.09* 1.01 ± 0.08* 1.28 ± 0.41 1.08 ± 0.22* 1.03 ± 0.10*
LD WMSI 1.13 ± 0.26 1.02 ± 0.08* 1.01 ± 0.08* 1.20 ± 0.36 1.02 ± 0.06* 1.01 ± 0.05*
HD WMSI 1.33 ± 0.40 1.09 ± 0.20* 1.04 ± 0.14* 1.38 ± 0.43 1.08 ± 0.16* 1.04 ± 0.13*
DSE induced-ischemia (%) 44 (41) 4 (17)* 7 (9)* 49 (38) 4 (16)* 7 (12)*
* P \ 0.05 versus non DLVO
EDD end-diastolic diameter, EDS end-systolic diameter, IVSTd and IVSTs diastolic and systolic interventricular septal thickness,
PWTd and PWTs diastolic and systolic posterior wall thickness, RWT relative wall thickness, LVMH left ventricular mass corrected
for height-2.7, LV EF left ventricular ejection fraction
Table 4 Diastolic
parameters according to
development of DLVO in
diabetic patients
* P \ 0.05 versus
Moderate DLVO;
 P \ 0.05 versus Severe
DLVO
DT deceleration time, IVRT
isovolumin relaxation time,
Vp E wave propagation
velocity; E0 E0 wave annular
velocity
Non DLVO
(n = 107)
Moderate DLVO
(n = 24)
Severe DLVO
(n = 81)
E wave (m/s) 0.68 ± 0.18* 0.80 ± 0.21 0.72 ± 0.20
A wave (m/s) 0.81 ± 0.15* 0.94 ± 0.25 0.87 ± 0.16
E/A 0.87 ± 0.25 0.87 ± 0.23 0.84 ± 0.24
DT (m/s) 227 ± 65 211 ± 58 226 ± 64
IVRT (m/s) 94 ± 20 89 ± 14 87 ± 14
EVp (m/s) 0.41 ± 0.08* 0.46 ± 0.08 0.49 ± 0.10*
E/Vp 1.77 ± 0.35 1.65 ± 0.27 1.53 ± 0.37
E0 (m/s) 0.11 ± 0.3 0.11 ± 0.3 0.11 ± 0.3
E/E0 7.1 ± 2.8 7.3 ± 2.5 6.8 ± 2.1
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patients with DLVO, given the very low number of
cardiac events, it was not possible to identify any
significant predictive parameter; in subjects without
DLVO, age, diabetes length, baseline LV dimension
and global systolic function were not different
according to cardiac events’ occurrence, but peak
stress WMSI (1.29 ± 0.37 in patients without
vs. 1.71 ± 0.40 in patients with cardiac events,
P = 0.001) was significantly higher in patients with
a worse prognosis.
Discussion
Our study demonstrated that in a population including
only patients with suspected CAD, DSE-provoked
DLVO had a very high prevalence, especially among
diabetic patients. In non-diabetic patients, increasing
age independently determined a reduced development
of such a response; a preserved systolic function
demonstrated the highest predictive power, both
expressed as a normal baseline LV EF and a low
HD WMSI, that indicates a close to normal segmental
kinesis at peak DSE and excludes an extensive
ischemic response. In diabetic patients, the main
echocardiographic parameter associated with DLVO
in diabetic patients was a reduced LV dimension;
during follow-up, rate of new major cardiac events
was very low, but significantly higher among patients
without DLVO.
DSE and DLVO
Development of an hyperdynamic response to dobu-
tamine, with systolic cavity obliteration and intra-
ventricular obstruction, was reported for the first time
in the early nineties [19] and occurred in about 20%
of patients undergoing DSE; it was initially advo-
cated as a possible mechanism to explain the
development of hypotension during the test. Follow-
ing studies didn’t confirm this hypothesis and iden-
tified predisposing factors to such a response in
female sex, baseline small LV dimensions and
normal LV EF [11, 20]; although presence of DLVO
reduced DSE sensitivity, especially for single-vessel
disease, it showed a favorable long-term prognostic
value [10]. Clinical relevance of DLVO remains a
topic [21] of debate, for previous conflicting reports
[20, 22, 23].
In our study group, DLVO prevalence was higher
compared with several previous studies, especially
among diabetic patients: differences in DLVO defi-
nition and in study entry criteria can in part explain
these discrepancies. In this study we excluded
patients with ascertained CAD that were included in
several previous reports and are less likely to develop
DLVO; in fact, previous ischemic episodes fre-
quently determine LV enlargement and baseline wall
motion abnormalities, with reduced LV EF, a pattern
that often precludes DLVO development. Our results
were comparable with two previous studies [12, 13],
that included only patients evaluated for chest pain,
with angiographically normal coronary arteries. They
found a DLVO prevalence similar to what we found,
but they were not able to demonstrate any difference
in LV dimensions and function between patients with
and without DLVO, a discrepancy with our work
that could be due to the smaller size of their study
populations.
We couldn’t confirm previously reported associa-
tion of DLVO with female sex; we otherwise found
that, among non diabetic subjects, DLVO developed
less frequently in the elderly: this data was probably
due to a significantly higher prevalence of inducible
ischemia in old subjects. We didn’t observe any
association between DLVO and hypotension during
DSE, both among diabetic and non-diabetic patients.
Among D- subjects, patients who developed
DLVO frequently experienced chest pain during
DSE, in agreement with previous report: given the
very low prevalence of an ischemic response among
these subjects, this symptom could be due to a
microvascular angina determined by the very high
work load imposed to the LV by DLVO. The very
high prevalence of arterial hypertension and dyslipi-
demia observed in our study population could also
facilitate such a response.
Diabetes and DLVO
In our study group, DLVO prevalence was dispro-
portionably high among diabetic patients: this is a
new finding because data about prevalence of diabe-
tes in patients with or without DLVO were not
reported in several previous studies or there were not
significant differences; only Secknus et al. [10]
reported a significant minor prevalence of DLVO in
diabetic patients.
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Our results are otherwise in agreement with the
study of Coisne et al. [16] who examined by DSE 49
diabetic patients with suspected CAD and found a
DLVO prevalence of 59%, significantly higher
respect to the prevalence of 22% observed in non-
diabetic patients included as control group. They
could not demonstrate significant differences in LV
geometry between patients with and without DLVO,
both diabetic or not; in agreement with our results,
heart rate in diabetic patients was higher respect to
the control group before and at the end of the test.
In our study population in D? subjects, the LV
geometry associated with a higher prevalence of
DLVO was characterized by smaller end-systolic and
end-diastolic dimension, lower mass index and higher
RWT: this pattern represents a truly ‘‘normal’’ LV
geometry, on which the positive inotropic effect of
dobutamine can fully exert its effect, determining a
marked increase in contractility. On the other hand,
prevalence of LV hypertrophy was significantly
lower in patients who developed DLVO. Develop-
ment of hypertrophy, in response of a chronic
pressure overload probably represented in these
patients by arterial hypertension, is characterized by
myocyte growth, since the proliferative capacity of
cardiac myocytes is absent or at best very limited
[24]; this process is associated with activation of a
molecular program that determines an altered intra-
cellular calcium handling, increased rate of apoptosis
and enhanced extracellular matrix deposition leading
to reduced myocardial relaxation. All these modifi-
cations interfere with myocardial contractility and
probably prevent the marked hypercontractility
required to develop DLVO. Moreover LV hypertro-
phy was found to be associated with increased
morbidity and mortality, that we did not find in this
population, especially in patients with DLVO.
Diastolic function was significantly better in
patients with DLVO, both considering single param-
eters and prevalence of categorized diastolic dys-
function. We found a discrepancy between different
diastolic parameters, as according to Vp values the
difference was significant while according to E/E0 it
was not. Although both Vp and E0 reflect LV
relaxation property, this discrepancy could be due
to the fact that in normal heart Vp is more preload-
independent than mitral annular velocity [18] and can
accurately evaluate the presence or absence of an
abnormal relaxation. Given the higher prevalence of
treatment with diuretics among D? patients with
DLVO, the associated decrease in preload could
determine a false reduction of E0 and a concomitant
increase in E/E0 in patients with DLVO. E/E0, whose
mean value was normal in all groups, could therefore
be slightly increased in patients without DLVO for
relaxation abnormalities and in patients with DLVO
for decreased preload.
LV segmental wall motion was better all during
the test and an ischemic response developed in a very
limited proportion of patients. Heart rate was higher
in diabetic respect to non-diabetic patients both
baseline and all during the test; diabetic patients
who developed DLVO showed higher heart rate at
HD infusion respect to diabetic patients without
DLVO.
Development of DLVO during DSE in diabetic
patients seems therefore a result of several mecha-
nisms that variably combine to bring such a response:
a normal heart, considering both systolic and diastolic
dimensions and function, a relative hypovolemia
induced by diuretic treatment and an increased heart
rate at rest and during stress.
The presence of a significantly higher heart rate,
both at rest and during the test, could be an early sign
of parasympathetic dysfunction, leaving an unbal-
anced prevalence of sympathetic drive of cardiac rate
and contractility. In fact, although diabetic autonomic
neuropathy (DAN) [25, 26] is a system-wide disor-
ders, affecting all parts of the autonomic nervous
system, it manifests first in longer nerves, such as
vagus nerve, which is the longest of such system and
is responsible of cardiac parasympathetic innervation.
It is possible that, in presence of a narrow ventricle,
dobutamine induced a disproportionally high increase
in contractility, resulting in cavity obliteration and
DLVO development. Other indirect signs associated
with DAN, like diabetes’ duration and peripheral
neuropathy, were not different between patients with
and without DLVO, but this response could be an
early feature of this diabetic complication.
Prognostic value of DLVO
Beyond DLVO pathogenesis, in this diabetic popu-
lation evaluated with DSE for CAD screening we
confirmed the positive prognostic value of DLVO
development: cardiac events during follow-up were
few, but all except one restricted to patients without
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DLVO. It doesn’t seem like that we lost a diagnosis
of CAD in a significant proportion of patients due to
DLVO development as we know that CAD in
diabetic subjects portends a bad prognosis. This
follow-up results allow us to say that these patients,
with normal baseline LV geometry and function and
DLVO during DSE, represent a very low risk
population. We choose to define DSE-induced DLVO
as a maximum gradient of at least 36 mmHg, the
highest value reported in previous work [12, 16, 20]:
we can argue that to develop at least that gradient, or
higher, a normal global and segmental LV systolic
function is required and it is very unlikely the
underlying existence of a CAD, also in case of
monovasal involvement. A careful management of
coexisting cardiovascular risk factors remains man-
datory for its proved prognostic advantage [27], but
further tests to evaluate CAD existence don’t seem to
yield significant benefits.
The main limitations of this study are the retro-
spective design and the lack of coronary angiographic
data, to confirm DSE results; follow-up results can in
part overcome this limitation because, beyond pres-
ence of anatomical coronary lesions, we were able to
ascertain the very low prevalence of cardiac events in
patients with DLVO. We also had not any data about
heart rate variability that could support our conclu-
sion: however, this is a possible future area of
investigation, to better clarify the inotropic effect of
dobutamine according to LV geometry and the role of
dobutamine stress echocardiography in CAD screen-
ing in diabetic patients.
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